Increased plasma levels of plasminogen activator inhibitor-1 and soluble vascular cell adhesion molecule after triacylglycerol infusion in man

Thrombosis and Haemostasis

Volumn 90, Issue 3, 2003, Pages 422-428

  Krebs, Michael ^a   Geiger, Margarethe ^a   Polak, Kaija ^a   Vales, Anja ^a   Schmetterer, Leopold ^a   Wagner, Oswald F ^a   Waldhäusl, Werner ^a   Binder, Bernd R ^a   Roden, Michael ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Adhesion molecules; Fibrinolysis; Free fatty acids; Insulin resistance; PAI 1; Vascular disease; VCAM 1

Indexed keywords

ADIPSIN; FATTY ACID; GLUCOSE; HEPARIN; INSULIN; INTRALIPID; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROTEINASE; RECOMBINANT HUMAN INSULIN; SODIUM CHLORIDE; SOMATOSTATIN; TISSUE PLASMINOGEN ACTIVATOR; TRIACYLGLYCEROL; VASCULAR CELL ADHESION MOLECULE 1;

ADIPOCYTE; ADULT; ARTICLE; ATHEROSCLEROSIS; CIRCADIAN RHYTHM; CLINICAL PROTOCOL; CONTINUOUS INFUSION; CONTROLLED STUDY; CORRELATION ANALYSIS; FATTY ACID BLOOD LEVEL; GLUCOSE BLOOD LEVEL; HUMAN; HUMAN EXPERIMENT; HYPERLIPIDEMIA; IMMUNOASSAY; INFUSION; INSULIN BLOOD LEVEL; MALE; NORMAL HUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; STATISTICAL ANALYSIS; STIMULATION; THROMBOSIS; TRIACYLGLYCEROL BLOOD LEVEL; VASCULAR TISSUE;

EID: 0141429031     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/th03-07-0457     Document Type: Article

References (61)

1. Binder BR. Physiology and pathophysiology of the fibrinolytic system. Fibrinolysis 1995; 9 (Suppl 1): 3-8.
2. Hamsten A, et al. Increased plasma levels of a rapid inhibitor of tissue plasminogen activator in young survivors of myocardial infarction. N Engl J Med 1985; 313: 1557-63.
3. Juhan-Vague I, Alessi MC. Fibrinolysis and risk for coronary artery disease. Fibrinolysis 1996; 10: 127-36.
4. Eitzman DT, et al. Plasminogen activator inhibitor-1 deficiency protects against atherosclerosis progression in the mouse carotid artery. Blood 2000; 96: 4212-5.
5. Juhan-Vague I, Alessi MC. Plasminogen activator inhibitor 1 and atherothrombosis. Thromb Haemost 1993; 70: 138-43.
6. Byberg L, et al. Plasminogen activator inhibitor-1 activity is independently related to both insulin sensitivity and serum triglycerides in 70-year-old men. Arterioscler Thromb Vasc Biol 1998; 18: 258-64.
7. Juhan-Vague I, Alessi MC. PAI-1, obesity, insulin resistance and risk of cardiovascular events. Thromb Haemost 1997; 78: 656-660.
8. McGarry JD. What if Minowski had been ageusic? An alternative angle an diabetes. Science 1992; 258: 766-70.
9. Reaven GM. Role of insulin resistance in human disease. Diabetes 1988; 37: 1595-607.
10. Alessi MC, et al. Up-regulation of PAI-1 synthesis by insulin and proinsulin in Hep G2 cells but not in endothelial cells. Fibrinolysis 1995; 9: 237-42.
11. Kooistra T, et al. Plasminogen activator inhibitor 1: Biosynthesis and mRNA levels are increased by insulin in cultured human hepatocytes. Thromb Haemost 1989; 62: 723-8.
12. Banfi C, et al. Linoleic acid enhances the secretion of plasminogen activator inhibitor type 1 by Hep G2 cells. J Lipid Res 1997; 38: 860-9.
13. Schneider DJ, Sobel BE. Synergistic augmentation of expression of plasminogen activator inhibitor type-1 induced by insulin, very-low-density lipoproteins, and fatty acids. Coron Art Dis 1996; 7: 813-7.
14. Eriksson P, et al. Very-low-density lipoprotein response element in the promoter region of the human plasminogen activator inhibitor-1 gene implicated in the impaired fibrinolysis of hypertriglyceridemia. Arterioscler Thromb Vasc Biol 1997; 18: 20-6.
15. Stiko-Rahm A, et al. Secretion of plasminogen activator inhibitor-1 from cultured human umbilical vein endothelial cells is induced by very low density lipoprotein. Arteriosclerosis 1990; 10: 1067-73.
16. Karikó K, et al. Stimulatory effect of unsaturated fatty acids on the level of plasminogen activator inhibitor-1 mRNA in cultured human endothelial cells. FEBS Lett 1995; 361: 118-22.
17. Nilsson L, et al. Unsaturated fatty acids increase plasminogen activator inhibitor-1 expression in endothelial cells. Arterioscler Thromb Vasc Biol 1998; 18: 1679-85.
18. Nordt TK, et al. Induction of plasminogen activator inhibitor type-1 (PAI-1) by proinsulin and insulin in vivo. Circulation 1995; 91: 764-70.
19. Calles-Escandon J, et al. Induction of hyperinsulinemia combined with hyperglycemia and hypertriglyceridemia increases plasminogen activator inhibitor 1 in blood in normal human subjects. Diabetes 1998; 47: 290-3.
20. Vuorinen-Markkola H, et al. No evidence for short-term regulation of plasminogen activator inhibitor activity by insulin in men. Thromb Haemost 1992; 67: 117-20.
21. Leeuwenberg JFM, et al.. E-selectin and intercellular adhesion molecule-1 are released by activated human endothelial cells in vitro. Immunology 1992; 77: 543-9.
22. Pigott R, et al.. Soluble forms of E-selectin, ICAM-1 and VCAM-1 are present in the supernatants of cytokine activated cultured endothelial cells. Biochem Biophys Res Commun 1992; 187: 584-9.
23. Wagner OF, Jilma B. Putative role of adhesion molecules in metabolic disorders. Horm Metab Res 1997; 29: 627-30.
24. Huber K, et al.. Hepatic synthesis and clearance of components of the fibrinolytic system in healthy volunteers and in patients with different stages of liver cirrhosis. Thromb Res 1991; 62: 491-500.
25. Van Griensven JM, et al.. Effects of increased liver blood flow on the kinetics and dynamics of recombinant tissue-type plasminogen activator. Clin Pharmacol Ther 1996; 60: 504-11.
26. Lansink M, et al.. Increased clearance explains lower plasma levels of tissue-type plasminogen activator by estradiol: Evidence for potently enhanced mannose receptor expression in mice. Blood 1999; 94: 1330-6.
27. White RT, et al.. Human adipsin is identical to complement factor D and is expressed at high levels in adipose tissue. J Biol Chem 1992; 267: 9210-3.
28. Alessi MC, et al.. Relation between plasma PAI activity and adipsin levels. Thromb Haemostas 1995; 74: 1200-2.
29. Mavri A, et al.. Impact of adipose tissue on plasma plasminogen activator inhibitor-1 in dieting obese women. Arterioscler Thromb Vasc Biol 1999; 19: 1582-7.
30. Krebs M, et al.. Free fatty acids inhibit the glucose stimulated increase of intramuscular glucose-6-phosphate concentrations in humans. J Clin Endocrinol Metab 2001; 86: 2153-60.
31. Hultin M, et al.. Release of lipoprotein lipase to plasma by triacylglycerol emulsions. Biochim Biophys Acta 1992; 1125: 97-103.
32. Gerich JE, et al.. Effects of somatostatin on plasma glucose and glucagon levels in human diabetes mellitus. Pathophysiologic and therapeutic implications. N Engl J Med 1974; 291: 544-7.
33. Roden M, et al.. The roles of insulin and glucagon in the regulation of hepatic glycogen synthesis and turnover in humans. J Clin Invest 1996; 97: 642-8.
34. McGowan MW, et al.. A peroxidase-coupled method for the colorimetric determination of serum triglycerides. Clin Chem 1983; 29: 538-42.
35. Huber K, et al.. Circadian fluctuations in plasma levels of tissue plasminogen activator antigen and plasminogen activator inhibitor activity. Fibrinolysis 1989; 3: 41-3.
36. Juhan-Vague I, et al.. Daytime fluctuations of plasminogen activator inhibitor 1 (PAI-1) in populations with high PAI-1 levels. Thromb Haemost 1992; 67: 76-82.
37. Urano T, et al.. Fluctuations of tPA and PAI-1 antigen levels in plasma: Difference of their fluctuation patterns between male and female. Thromb Res 1990; 60: 133-9.
38. Agnelli G, et al.. Additive effects of dDAVP and standard heparin in increasing plasma t-PA. Thromb Haemost 1989; 61: 507-10.
39. Huber K, et al.. Heparin induces t-PA antigen plasma levels in patients with unstable angina: No evidence for clinical benefit of heparinization during the initial phase of treatment. Thromb Res 1989; 55: 779-84.
40. Myrup B, et al.. No effect of unfractionated or low molecular weight heparin treatment on markers of vascular wall and hemostatic function in incipient diabetic nephropathy. Diabetes Care 1997; 20: 1615-9.
41. Van Hinsberg VW, et al.. Tumor necrosis factor increases the production of plasminogen activator inhibitor in human endothelial cells in vitro and in rats in vivo. Blood 1988; 72: 1467-73.
42. Loskutoff DJ, et al. The adipocyte and hemostatic balance in obesity. Studies of PAI-1. Arterioscler Thromb Vasc Biol 1998; 18: 1-6.
43. Loskutoff DJ. Regulation of PAI-1 gene expression. Fibrinolysis 1991; 5: 197-206.
44. Booth NA, et al.. Plasminogen activator inhibitor (PAI-1) in plasma and platelets. Br J Haematol 1988; 70: 327-33.
45. Asplund-Carlson A, et al.. Relationship between plasma plasminogen activator inhibitor-1 activity and VLDL triglyceride concentration, insulin levels and insulin sensitivity: Studies in randomly selected normo- and hypertriglyceridaemic men. Diabetologia 1993; 36: 817-25.
46. Agnelli G, et al. Effects of standard heparin and low molecular weight heparin (Kabi 2165) on fibrinolysis. Thromb Haemost 1987; 60: 311-3.
47. Böhm T, et al. Isolation and characterization of tissue-type plasminogen activator-binding proteoglycans from human umbilical vein endothelial cells. Arterioscler Thromb Vasc Biol 1996; 16: 665-72.
48. Rappaport RS, et al.. Heparin potentiates endothelial cell growth factor stimulation of plasminogen activator synthesis by dipoloid human lung fibroblasts. Thromb Haemost 1988; 59: 514-22.
49. Hackmann A, et al.. Levels of soluble cell adhesion molecules in patients with dyslipidemia. Circulation 1996; 93: 1334-8.
50. Grainger DJ, et al.. Transforming growth factor beta is sequestered into an inactive pool by lipoproteins. J Lipid Res 1997; 38: 2344-52.
51. Harris HW, et al. The lipemia of sepsis: Triglyceride-rich lipoproteins as agents of innate immunity. J Endotoxin Res 2000; 6: 421-30.
52. Kemme MJ, et al.. No influence of acute hypertriglyceridemia on plasma t-PA in healthy male volunteers. Thromb Res 2001; 103: 9-16.
53. Altomare DF, et al. Reduction of plasma levels of tissue plasminogen activator after infusion of a lipid emulsion in humans. J Parenter Enteral Nutr 1993; 17: 274-6.
54. Sironi L, et al.. Plasminogen activator inhibitor type-1 synthesis and mRNA expression in HepG2 cells are regulated by VLDL. Arterioscler Thromb Vasc Biol 1996; 16: 89-96.
55. Kooner JS, et al.. Abdominal obesity, impaired nonesterified fatty acid suppression, and insulin-mediated glucose disposal are early metabolic abnormalities in families with premature myocardial infarction. Arterioscler Thromb Vasc Biol 1998; 18: 1021-6.
56. Boden G, et al.. Mechanisms of fatty acid-induced inhibition of glucose uptake. J Clin Invest 1994; 93: 2438-46.
57. Bonadonna RC, et al.. Time dependence of the interaction between lipid and glucose in humans. Am J Physiol 1989; 257: E49-56.
58. Yki-Järvinen H, et al. Effect of free fatty acids on glucose uptake and nonoxidative glycolysis across human forearm tissues in the basal state and during insulin stimulation. J Clin Endocrinol Metab 1991; 72: 1268-77.
59. Mingrone G, et al.. Triglyceride-induced diabetes associated with familial lipoprotein lipase deficiency. Diabetes 1999; 48: 1258-63.
60. Meijssen S, et al.. In vivo evidence of defective postprandial and postabsorptive free fatty acid metabolism in familial combined hyperlipidemia. J Lipid Res 2000; 41: 1096-102.
61. Kumar S, et al.. Suppression of non-esterified fatty acids to treat type A insulin resistance syndrome. Lancet 1994; 343: 1073-4.